Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1489
Shown on this page
12
Current sort
Recently updated
Campus scope
Massachusetts General Hospital, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Massachusetts General Hospital, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 157–168 of 1,489 matching trials with a site at Massachusetts General Hospital, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1Phase 2 Interventional

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT05919264
Status at this site: Recruiting
Conditions
Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, Familial Adenomatous Polyposis (FAP), Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Adamantinomatous Craniopharyngioma
Interventions
FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab
Drug
Lead sponsor
Parabilis Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more
Conditions
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
Interventions
Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
Not yet recruiting Not applicable Interventional

Digital Coach to Support Exposure Therapy Homework for Anxious Youth

NCT07666672
Site status not listed — check the official record
Conditions
Anxiety Disorders, OCD
Interventions
BraveBot, Self-Guided Exposure Therapy Homework
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 22 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
3
States / cities
Belmont, Massachusetts • Boston, Massachusetts • Cambridge, Massachusetts
Active, not recruiting Phase 2 Interventional Results available

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

NCT03224767
Site status not listed — check the official record
Conditions
BRAF V600E Mutation Present, Papillary Craniopharyngioma
Interventions
Vemurafenib, Cobimetinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
106
States / cities
Birmingham, Alabama • Auburn, California • Berkeley, California + 85 more
Active, not recruiting Phase 1 Interventional

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

NCT02886065
Site status not listed — check the official record
Conditions
Smoldering Multiple Myeloma
Interventions
Hiltonol, Citarinostat, Lenalidomide, PVX-410
Drug · Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more
Recruiting No phase listed Observational

Boston Lung Cancer Study (Molecular and Genetic Analysis of Lung Cancer)

NCT03029325
Status at this site: Recruiting
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cirrhosis, End Stage Liver DIsease, Liver Cirrhosis, Liver Disease Chronic
Interventions
Hepatology Home Hospital
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting No phase listed Observational

Molecular Epidemiology of Acute Respiratory Distress Syndrome (ARDS)

NCT00006496
Site status not listed — check the official record
Conditions
Acute Respiratory Distress Syndrome, Lung Diseases
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Not applicable Interventional

NeuroPathways Intervention for Brain Tumor Patients

NCT05976490
Status at this site: Recruiting
Conditions
Malignant Brain Tumor, Glioma, Coping Skills
Interventions
Information and Support Intervention, Usual supportive care
Behavioral · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting No phase listed Observational Accepts healthy volunteers

Family Members at INcreased-risk for Developing Inflammatory Bowel Disease

NCT06655415
Status at this site: Recruiting
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), IBD-unclassified (IBD-U), Indeterminate Colitis, Crohn's Disease Colon, Crohn's Colitis, Crohn's Ileocolitis, Crohn's Gastritis, Crohn's Jejunitis, Crohn's Duodenitis, Crohn's Esophagitis, Ulcerative Proctitis, Ulcerative Proctosigmoiditis
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Hurria Older PatiEnts (HOPE) With Breast Cancer Study

NCT01472094
Site status not listed — check the official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
17
States / cities
Duarte, California • New Haven, Connecticut • Chicago, Illinois + 12 more
Recruiting Not applicable Interventional

LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease

NCT05998330
Status at this site: Recruiting
Conditions
Liver Disease Chronic, End Stage Liver DIsease, Cirrhosis, Cirrhosis, Liver, Advanced Cirrhosis
Interventions
LiverPAL
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts

About this Massachusetts General Hospital institution page

What this page lists
ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Massachusetts General Hospital at any site, browse by condition, or browse by U.S. city.